Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101637 | 0.89 | NR3C1 (0.39) | PDE10ANR3C1PTGS1 | |
| SCHEMBL7103450 | 0.88 | BRD4 (0.31) | BRD4PDE10AHTT | |
| SCHEMBL7248476 | 0.88 | BRAF (0.34) | CYP2C9BRAFPDE10AMRGPRX1HTT | |
| SCHEMBL7248382 | 0.82 | NR3C1 (0.41) | CYP2C9PDE10AMRGPRX1HTTNR3C1 | |
| SCHEMBL7248995 | 0.81 | BRD4 (0.40) | BRD4CYP2C9PDE10AHTTLMNA | |
| SCHEMBL7248295 | 0.78 | PGR (0.37) | BRD4BRAFHTTLMNAHPGD | |
| SCHEMBL7248504 | 0.78 | PSIP1 (0.37) | BRD4CYP2C9BRAFMRGPRX1PSIP1 | |
| SCHEMBL7103402 | 0.77 | MRGPRX1 (0.34) | BRAFPDE10AMRGPRX1HTTPTGS1 | |
| SCHEMBL7247802 | 0.76 | SLC40A1 (0.33) | PDE10AHTTLMNAHPGD | |
| SCHEMBL7254139 | 0.75 | HPGD (0.31) | HTTLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | BRD4 26/4885CYP2C9 1355/4885BRAF 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.